GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

Inicio・Lista de Acciones・AstraZeneca PLC
Search

AstraZeneca PLC

Cerrado

SectorSanidad

13,514 -3.07

Compra Fuerte

Precios actualizados 1 may 2026, 15:29 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

13514

Máximo

13632

Métricas clave

By Trading Economics

Ingresos

1.6B

3.9B

Ventas

-215M

15B

P/B

Media del Sector

27.389

51.415

BPA

1.29

Rentabilidad por dividendo

1.75

Margen de beneficios

25.602

Empleados

96,100

EBITDA

1.1B

5.7B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+17.01% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.75%

2.34%

Próximas Ganancias

27 jul 2026

Próxima Fecha de Ex Dividendo

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-8.7B

282B

Apertura anterior

13517.07

Cierre anterior

13514

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

53 / 345 Clasificación en Healthcare

AstraZeneca PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 16:28 UTC

Ganancias

Correction to AstraZeneca Update

DJ

Leer

29 abr 2026, 15:11 UTC

Ganancias

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

DJ

Leer

29 abr 2026, 06:31 UTC

Ganancias

AstraZeneca Gets Revenue Boost From Cancer Drugs

DJ

Leer

27 mar 2026, 10:04 UTC

Noticias de Eventos Importantes

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

DJ

Leer

13 may 2026, 12:29 UTC

Charlas de Mercado

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

DJ

Leer

13 may 2026, 11:54 UTC

Charlas de Mercado

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

DJ

Leer

1 may 2026, 09:31 UTC

Charlas de Mercado

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

DJ

Leer

29 abr 2026, 10:29 UTC

Charlas de Mercado
Ganancias

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

DJ

Leer

29 abr 2026, 10:06 UTC

Charlas de Mercado
Ganancias

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

Leer

29 abr 2026, 09:53 UTC

Charlas de Mercado
Ganancias

AstraZeneca Seems in Fine Health -- Market Talk

DJ

Leer

29 abr 2026, 06:05 UTC

Ganancias

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

DJ

Leer

29 abr 2026, 06:04 UTC

Ganancias

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

DJ

Leer

29 abr 2026, 06:04 UTC

Ganancias

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

DJ

Leer

29 abr 2026, 06:03 UTC

Ganancias

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

DJ

Leer

29 abr 2026, 06:03 UTC

Ganancias

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

DJ

Leer

29 abr 2026, 06:02 UTC

Ganancias

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

DJ

Leer

29 abr 2026, 06:01 UTC

Ganancias

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

DJ

Leer

29 abr 2026, 06:01 UTC

Ganancias

AstraZeneca Backs 2026 View

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Adj EPS $2.58

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Rev $15.29B

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Pretax Pft $3.91B

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Oper Pft $4.25B

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Net Pft $3.08B

DJ

Leer

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q EPS $1.97

DJ

Leer

27 abr 2026, 10:48 UTC

Charlas de Mercado

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

DJ

Leer

10 abr 2026, 11:57 UTC

Charlas de Mercado

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

DJ

Leer

10 abr 2026, 10:26 UTC

Charlas de Mercado
Ganancias

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

DJ

Leer

2 abr 2026, 09:16 UTC

Charlas de Mercado

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

DJ

Leer

27 mar 2026, 10:40 UTC

Charlas de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

DJ

Leer

27 mar 2026, 10:17 UTC

Charlas de Mercado

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

AstraZeneca PLC previsión

Precio Objetivo

By TipRanks

17.01% repunte

Estimación a 12 Meses

Media 16,076.92 GBX  17.01%

Máximo 18,600 GBX

Mínimo 11,300 GBX

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

13

Comprar

1

Mantener

1

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para AstraZeneca PLC Dist en los últimos 3 meses.

Sentimiento

By Acuity

53 / 345 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Otras acciones del sector

GSK

GlaxoSmithKline PLC

1,858.5

↓-0.83%